GlassScriptPhysician profile
Duyen K Nguyen
NPI 1619288347
$11,017.79
in general payments reported to CMS, 2019-2025
36 companies · $2,832 in 2025
The $2,832 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $807 · 2020: $964 · 2021: $966 · 2022: $1,886 · 2023: $1,872 · 2024: $1,692 · 2025: $2,832.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,396.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,395.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,888.46 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Genzyme Corporation | $1,523.26 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,029.48 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Regeneron Healthcare Solutions, INC. | $706.07 | 2019-2024 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $643.27 | 2021-2025 | Cuvitru, Takhzyro, Hyqvia |
| Genentech USA, INC. | $562.30 | 2019-2025 | Xolair |
| Grifols USA, LLC | $485.26 | 2019-2025 | Xembify |
| Kaleo, INC. | $428.35 | 2020-2024 | Auvi-Q |
| Novartis Pharmaceuticals Corporation | $408.68 | 2022-2025 | |
| Ars Pharmaceuticals Operations, INC. | $302.13 | 2025 | Neffy |
| Pfizer INC. | $215.12 | 2019-2024 | |
| Blueprint Medicines Corporation | $212.80 | 2024-2025 | Ayvakit |
| Incyte Corporation | $195.43 | 2021-2023 | Opzelura |
| Amgen INC. | $183.67 | 2022-2025 | Tezspire |
| Adma Biomanufacturing LLC | $170.83 | 2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alk-Abello, INC | $140.22 | 2019-2023 | Odactra, Grastek, Ragwitek |
| Csl Behring | $122.09 | 2019-2025 | Haegarda, Hizentra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $103.72 | 2019-2021 | |
| Abbvie INC. | $99.05 | 2024 | |
| Optinose US, INC. | $98.70 | 2019-2023 | |
| Teva Pharmaceuticals USA, INC. | $64.14 | 2020-2021 | |
| Pharming Healthcare, INC. | $51.16 | 2025 | Ruconest |
| Octapharma USA, INC. | $46.25 | 2023 | Cutaquig |
| Cycle Pharmaceuticals INC | $41.26 | 2025 | Sajazir |
| Kowa Pharmaceuticals America, INC. | $34.83 | 2025 | Zoryve |
| Aimmune Therapeutics, INC. | $32.01 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $31.92 | 2019 | |
| Viatris Specialty LLC | $30.33 | 2025 | Yupelri |
| Organon LLC | $30.29 | 2025 | Vtama |
| Phadia US INC. | $24.98 | 2024 | Immunocap |
| Kedrion Biopharma, INC. | $23.99 | 2025 | Rhogam Ultra-Filtered Plus, Albuked, Gammaked |
| Sanofi Pasteur INC. | $20.24 | 2022 | |
| Leo Pharma INC. | $19.32 | 2025 | Anzupgo |
| Galderma Laboratories, L.P. | $18.41 | 2025 | Nemluvio |
| Merck Sharp & Dohme LLC | $16.30 | 2023 | |
| Almirall LLC | $13.47 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Duyen Nguyen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.